The efficacy and safety of thrombolytic therapy of acute coronary syndrome with ST-segment elevation in pre-hospital stage


Cite item

Abstract

The article provides an analysis of the results of thrombolytic therapy in 85 patients with acute coronary syndrome with ST-segment elevation. The patients were divided into groups according to the time from the onset of pain to the conduction of thrombolysis: group 1 CLT up to 1 hour, group 2 with CLT from 1 to 2 hours, group 3 with CLT more than 2 hours. It is shown that the pre-hospital thrombolysis with the use of fibrin-specific plasminogen activator conducted within 1 hour from the onset of the symptoms of the disease is the most effective and safe. When you increase the time before treatment, the effectiveness is reduced.

About the authors

M G Prozhoga

Email: Michail_pro@mail.ru

References

  1. Antman E.M., Anbe D.T., Armstrong P.W. et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the ACC/AHA Task Force onPractice Guidelines (Committee to Revise the 1999 Guidelines on the Management of Patients With Acute Myocardial Infarction. J Am Coll Cardiol. 2004; 44: 671-719.
  2. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J. 2008; 29: 2909-2945.
  3. Sinnaeve P.R., Alexander J., Belmans A. et al. One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction. Am Heart J. 2003; 146 (1): 27-32.
  4. Арутюнов Г.П., Розанов А.В. Тенектеплаза. Первый опыт применения в Российской Федерации. Сердце. 2006; 6: 284-287.
  5. Фокина Е.Г., Грачев В.Г., Липченко А.А. и др. Догоспиальная тромболитическая терапия тенектеплазой у больных с инфарктом миокарда с подъемом сегмента ST. Кардиология. 2008: 4; 14-18.
  6. Gruppo Italiano per lo Studio della Streptochinasi nell/Infarto Miocardico (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986; 1: 397-407.
  7. Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST электрокардиограммы. Российские рекомендации. Разработаны Комитетом экспертов Всероссийского научного общества кардиологов 2007. htpp://www.cardiosite.ru
  8. Antman E.M., Anbe D.T., Armstrong P.W. et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the ACC/AHA Task Force onPractice Guidelines (Committee to Revise the 1999 Guidelines on the Management of Patients With Acute Myocardial Infarction. J Am Coll Cardiol. 2004; 44: 671-719.
  9. De Luca G., Suryapranata H., Ottervanger J.P., Antman E.M. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction. Every minute of delay counts. Circulation 2004; 109: 1223-1225.
  10. Steg P.G., Bonnefoy E., Chahaud S. et al. for the CAPTIM investigators. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty. Data from the CAPTIM randomized clinical trial. Circulation 2003; 108: 2851-2856.
  11. Van de Werf F., Ardissino D., Betriu A. et al. Management of acute myocardial infarction with ST segment elevation. The TASK force on the management of acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2003; 24: 28-66.
  12. The European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993; 329: 383-389.
  13. Wallentin L., Goldstein P., Amstrong P.W. et al. Efficacy and safety of tenecteplase in combination with the low-molecular weight heparin enoxaparin and the unfractioned heparin in the prehospital setting. The ASSENT-3 PLUS randomized trial. Circulation 2003; 108: 135-142.
  14. Taher T., Fu Y., Wagner G. et al. Aborted myocardial infarction in patients with ST-segment elevation. J Am Coll Cardiol 2004; 44: 38-43.
  15. Национальные клинические рекомендации ВНОК, Москва 2009.
  16. Van de Werf F, Cannon CP, Luyten A et al.Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J 1999; 137: 786-91.
  17. Cannon CP, Gibson CM, McCabe CH et al.TNK-tissue plasminogen activator comparedwith front-loaded alteplase in acute myocardialinfarction: results of the TIMI 10B trial. Thrombolysisin Myocardial Infarction (TIMI) 10 Binvestigators. Circulation 1998; 98: 2805-2814.

Copyright (c) 2014 Prozhoga M.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies